Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer
Abstract
Liquid biopsy is a powerful tool that can enable treatment decisions for metastatic prostate cancer patients with difficult‐to‐biopsy tumors. However, the detection of genomic alterations via liquid biopsy is limited by the fraction (tumor fraction [TF]) of circulating tumor DNA (ctDNA) within the total cell‐free DNA content. While prior work has preliminarily correlated TF with clinical features of prostate cancer, we sought to validate and provide additional resolution, such that a clinical practitioner might anticipate the probability of successful liquid biopsy profiling leveraging commonly assessed clinical and laboratory features.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 14, 2022
- Source ID
- 10.1002/pros.24331
Entities
People
- Emmanuel S. Antonarakis
- Geoffrey R. Oxnard
- Hanna Tukachinsky
- Marni Tierno
- Matthew C. Hiemenz
- Omar Hamdani
- Richard S P Huang
- Ryon P. Graf
- Sonja Alexander
- Virginia Fisher
Organizations
- Foundation Medicine
- United States Department of Defense
- University of Minnesota